Drug Profile
ODM 207
Alternative Names: ODM-207Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Aurigene Discovery Technologies
- Developer Orion
- Class Antineoplastics; Small molecules
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-I/II for Solid tumours (In the elderly, Late-stage disease, Metastatic disease, In adults) in Spain, France, Finland, United Kingdom (PO) (Orion pipeline, February 2022)
- 10 May 2019 Orion completes the phase I/II BETIDES trial in Solid tumours (In the elderly, In adults, Late-stage disease, Metastatic disease) in United Kingdom, Finland, Spain and France (PO) (EudraCT2015-004826-32)
- 09 Mar 2019 Pharmacodynamics data from a preclinical studies in Solid tumours presented at the 110th Annual Meeting of the American Association for Cancer Research (AACR-2019)